Article

Topical cyclosporine can handle more than dry-eye disease

Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Cambium Bio completes funding to help advance dry eye disease treatment
December 5th 2024

Cambium Bio completes funding to help advance dry eye disease treatment

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Neurotech CCO Scott Hunter passes away
December 5th 2024

Neurotech CCO Scott Hunter passes away

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery
December 5th 2024

VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery

Researchers: Nerve cells of blind mice retain their visual function
December 5th 2024

Researchers: Nerve cells of blind mice retain their visual function

© 2024 MJH Life Sciences

All rights reserved.